Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

Indacaterol/glycopyrronium is cost-effective compared to salmeterol/fluticasone in COPD: FLAME-based modelling in a Swedish population

Abstract Background This study assessed the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in chronic obstructive pulmonary disease (COPD) patients with moderate to very severe airflow limitation and ≥1 exacerbation in the preceding year. Methods A pre...

Full description

Bibliographic Details
Main Authors: Leif Bjermer, Job F. M. van Boven, Madlaina Costa-Scharplatz, Dorothy L. Keininger, Florian S. Gutzwiller, Karin Lisspers, Ronan Mahon, Petter Olsson, Nicolas Roche
Format: Article
Language:English
Published: BMC 2017-12-01
Series:Respiratory Research
Subjects:
Chronic obstructive pulmonary disease
Indacaterol/glycopyrronium
Cost-effective
Exacerbation
Online Access:http://link.springer.com/article/10.1186/s12931-017-0688-5

Internet

http://link.springer.com/article/10.1186/s12931-017-0688-5

Similar Items